FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults

The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults. The agency described the clearance as the first oral drug indicated to treat dermatomyositis in adults, filling a gap in a disease area that has long relied on corticosteroids and off-label immunosuppressants.

Dermatomyositis is a rare autoimmune inflammatory condition marked by muscle weakness and distinctive skin rash. Because no oral therapy had previously carried a specific label for the disease in adults, an approved tablet formulation changes the treatment pathway for prescribing physicians.

Brepocitinib is an oral kinase inhibitor developed by Priovant Therapeutics, the immunology unit majority-owned by Roivant Sciences (ROIV). The asset had been the company's most closely watched late-stage program, and a first-in-class label is the type of outcome that determines whether an orphan-scale indication can support commercial launch spending.

The FDA announcement did not disclose pricing, launch timing or the specific dosing details in the release text. Investors will look to the company for those commercial specifics, along with the approved label language on safety monitoring, which is typically extensive for drugs in the kinase-inhibitor class.

For a rare disease with no prior oral option, the size of the eligible adult population and the speed of payer coverage will determine how much of the approval translates into revenue. The regulatory milestone itself removes the binary risk that had hung over the program.

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.